BioCentury
ARTICLE | Company News

CureVac, Boehringer Ingelheim deal

September 22, 2014 7:00 AM UTC

CureVac granted Boehringer exclusive, worldwide rights to develop and commercialize CureVac's CV9202. The vaccine is in a Phase Ib trial to treat metastatic non-small cell lung cancer (NSCLC). The deal includes a EUR35 million ($45.3 million) payment to CureVac, which is eligible for up to EUR430 million ($556.4 million) in milestones, plus royalties. CV9202 is an mRNA-based vaccine that was developed with CureVac's RNAactive technology. The vaccine codes for six antigens frequently expressed on NSCLC cells: melanoma-associated antigen family C 1 ( MAGEC1), MAGEC2, cancer/testis antigen 1B ( CTAG1B; NY-ESO-1), survivin (BIRC5), oncofetal antigen 5T4 and mucin 1 ( MUC1; CD227). ...